GlassScriptPhysician profile
George Petrossian
NPI 1821093444
$24,869.99
in general payments reported to CMS, 2019-2025
33 companies · $3,255 in 2025
The $3,255 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,549 · 2020: $2,337 · 2021: $3,612 · 2022: $1,935 · 2023: $2,385 · 2024: $5,797 · 2025: $3,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,754 · Travel and Lodging: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,753.98 |
| Travel and Lodging | $1,683.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $6,537.36 | 2019-2025 | Sapien 3 Ultra Resilia, Evoque, Pascal |
| Abbott Laboratories | $4,112.05 | 2019-2025 | Perclose Proglide, Mitraclip, Navitor |
| Medtronic, INC. | $4,092.44 | 2021-2025 | Corevalve Evolut R, Apollotm, Symplicity G3 |
| Medtronic Vascular, INC. | $2,815.29 | 2019-2020 | |
| Boston Scientific Corporation | $1,704.86 | 2019-2025 | Watchman Flx, Watchman Access System, Avvigo Guidance System |
| Ancora Heart, INC. | $834.96 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $832.75 | 2020-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $640.64 | 2019-2025 | Farxiga, Wainua |
| Abiomed | $589.83 | 2023-2025 | Impella |
| Amgen INC. | $345.05 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $333.55 | 2021-2025 | |
| Pfizer INC. | $325.29 | 2019-2025 | |
| Cvrx, INC. | $250.58 | 2024-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $226.07 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $185.38 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $157.49 | 2024-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $142.12 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $124.77 | 2019 | |
| Kestra Medical Technology Services, INC. | $99.56 | 2022-2025 | Assure Wcd |
| Inspire Medical Systems, INC. | $75.20 | 2025 | Inspire |
| Penumbra, INC. | $74.15 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $73.75 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $57.92 | 2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade 5f Vcs |
| Alnylam Pharmaceuticals INC. | $42.64 | 2021-2025 | Amvuttra |
| Esperion Therapeutics, INC. | $40.07 | 2024-2025 | Nexletol |
| Chiesi USA, INC. | $29.50 | 2024 | Cleviprex, Kengreal |
| Contego Medical, INC | $28.89 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.21 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $21.86 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $20.79 | 2024 | |
| Scpharmaceuticals INC. | $19.64 | 2025 | |
| Shockwave Medical, INC | $11.33 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Petrossian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.